Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-223044
Abstract: Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies. The development of biological agents specifically inhibiting the IL-5 pathway provided the opportunity to treat… read more here.
Keywords: targeting interleukin; interleukin pathway; remission; egpa ... See more keywords